Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.53 |
| ▸ | FAAH | O00519 | 4/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | CASP2 | P42575 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14728241 | 0.91 | GLP1R (0.61) | GLP1RFAAHDNM1LPAR1LPAR2 | |
| SCHEMBL14748061 | 0.91 | GLP1R (0.61) | GLP1RFAAHDNM1LPAR1LPAR2 | |
| SCHEMBL14748065 | 0.91 | GLP1R (0.61) | GLP1RFAAHDNM1LPAR1LPAR2 | |
| SCHEMBL12807271 | 0.90 | FAAH (0.62) | GLP1RFAAHDNM1LPAR1LPAR2 | |
| SCHEMBL13640865 | 0.90 | FAAH (0.62) | GLP1RFAAHDNM1LPAR1LPAR2 | |
| SCHEMBL24227203 | 0.90 | GLP1R (0.60) | GLP1RFAAHDNM1LPAR1LPAR2 | |
| SCHEMBL13640974 | 0.90 | FAAH (0.62) | GLP1RFAAHDNM1LPAR1LPAR2 | |
| SCHEMBL13815476 | 0.90 | GLP1R (0.59) | GLP1RFAAHDNM1CASP2 | |
| SCHEMBL14438843 | 0.89 | SELP (0.56) | GLP1RFAAH | |
| SCHEMBL19369946 | 0.89 | CES2 (0.54) | GLP1RFAAHDNM1LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150315260-A1 | EXENDIN-4 DERIVATIVES AS PEPTIDIC DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS | SANOFI (FR) | 2015-11-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315260-A1 | EXENDIN-4 DERIVATIVES AS PEPTIDIC DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS | GLP1R, GIPR, GCGR | GLP1R 1/4885FAAH 581/4885DNM1 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.